Novel Reversal Agent for Ticagrelor Gets FDA’s Breakthrough Tx Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PB2452 (PhaseBio), an investigational reversal agent for ticagrelor.
All articles by Diana Ernst, RPh
FDA Approves New Administration Option for Darzalex
The Food and Drug Administration (FDA) has approved a split-dosing regimen for Darzalex (daratumumab; Janssen), which provides clinicians the option of splitting the first infusion of daratumumab over 2 consecutive days.
Next post in Myeloma
